Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia (AKBA) to $4 from $6 and keeps an Overweight rating on the shares. Following a number of Q4/FY25 pre-releases in recent weeks and ahead of Q4 reporting, the firm is taking the opportunity to review and adjust its estimates for some of its commercial names, as well as some price targets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics Updates Executive Severance and Leadership Terms
- Akebia announces corporate updates, 2026 pipeline outlook
- Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
- Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
- Akebia announces first patient dosed in Phase 2 trial of praliciguat